Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)

This study has been completed.
Sponsor:
Collaborator:
Mentor Worldwide, LLC
Information provided by:
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT00444626
First received: March 7, 2007
Last updated: May 14, 2010
Last verified: March 2007

March 7, 2007
May 14, 2010
May 2007
February 2008   (final data collection date for primary outcome measure)
Mean Change from Baseline in the Blinded Evaluator's Assessment of Nasolabial Fold (NLF) Wrinkle Severity at Week 24 [ Time Frame: week 24 ] [ Designated as safety issue: No ]
The comparison between DGE and the FDA Approved Dermal Filler mean change in wrinkle improvement at Baseline and the Week 24 score for each NLF.
Complete list of historical versions of study NCT00444626 on ClinicalTrials.gov Archive Site
  • Participant's Pain Assessment During the Initial Treatment Measured on a Visual Analog Scale (VAS) [ Time Frame: day 1 ] [ Designated as safety issue: No ]
  • Change from Baseline in the Blinded Evaluator's Assessment of NLF Wrinkle Severity at Week 36 [ Time Frame: week 36 ] [ Designated as safety issue: No ]
  • Number of Participants with at least a 1 point Improvement from Baseline in the Blinded Evaluator's Assessment of Wrinkle Severity at Week 24 [ Time Frame: week 24 ] [ Designated as safety issue: No ]
  • Participant Product Preference at Week 24 [ Time Frame: week 24 ] [ Designated as safety issue: No ]
  • Participant Product Preference at Week 36 [ Time Frame: week 36 ] [ Designated as safety issue: No ]
  • Summary of Safety during the Initial Treatment Period [ Time Frame: weeks 0-36 ] [ Designated as safety issue: No ]
  • Summary of Safety during the Repeat Treatment Period [ Time Frame: weeks 36-47 ] [ Designated as safety issue: No ]
Subject pain assessment during and after injection procedure.
Not Provided
Not Provided
 
A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)
A Subject- and Evaluator-Blinded, Randomized, Multi-Center Study to Evaluate the Safety and Effectiveness of Injection With DGE Injectable Gel as Compared to an FDA-Approved Dermal Filler in Subjects Undergoing Cutaneous Correction of Nasolabial Folds

The purpose of this research study is to evaluate the safety and effectiveness of injection with DGE Injectable Gel (manufactured by Genzyme Biosurgery) as compared to injection with a Food and Drug Administration (FDA) approved dermal filler in patients undergoing cutaneous correction of the nasolabial folds (NLFs).

This study included an Initial and a Repeat Treatment period. The Initial Treatment period was a subject and evaluator-blinded, randomized split face study in which subjects received DGE in one nasolabial fold and Restylane in the other nasolabial fold.

In the Repeat Treatment Period, participants received DGE in both NLFs.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Facial Wrinkles at the Nasolabial Folds
  • Device: Dermal Gel Extra (DGE)
    Dermal Gel Extra (DGE) Injectable Gel was administered only to the nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable).
    Other Names:
    • PREVELLE Lift
    • hyaluronic acid and lidocaine
  • Device: Restylane
    Restylane was administered only to the nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable).
    Other Names:
    • dermal filler
    • hyaluronic acid
  • Experimental: DGE
    Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. For those that continued into the Repeat Treatment Period, they received DGE in all NLFs as an open-label treatment.
    Intervention: Device: Dermal Gel Extra (DGE)
  • Active Comparator: Restylane
    Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
    Intervention: Device: Restylane
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
140
July 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria (abbreviated list):

  • Bilateral nasolabial folds with severity score of 3 or 4 on the 6 point scale

Exclusion Criteria (abbreviated list):

  • Pregnant/lactating women
  • Subjects who have an allergy to lidocaine, prilocaine or other amide-type anesthetic
  • Had a chemical peel at the NLF area within 4 weeks prior to study entry. In addition, subjects were restricted from undergoing chemical peels at the NLF area for the duration of the study.
  • Had any treatment with Botox® injections:

    1. in the upper 1/3 of the face within 2 weeks prior to entry into the study, or
    2. in the lower 2/3 of the face within 24 weeks prior to entry. In addition, subjects were restricted from receiving Botox injections in the face for the duration of the study.
  • Received prior therapy to the face and/or neck (e.g., dermabrasion, face-lift, Thermage®,laser resurfacing, contour threads, non-ablative laser treatments) within 24 weeks prior to study entry. In addition, subjects were restricted from undergoing such therapy for the duration of the study.
  • Had previous tissue augmentation at the NLF area within 24 weeks prior to study entry.In addition, subjects were restricted from undergoing tissue augmentation at the NLF area for the duration of the study.
  • Had previous treatment at the NLF area with permanent implants (e.g., silicone,Softform®) or long-lasting fillers (e.g., RadiesseTM, Sculptra®, ArteFill® [Artecoll], or Bio-AlcamidTM). In addition, subjects were restricted from undergoing treatment with permanent implants or long-lasting fillers at the NLF area for the duration of the study.
  • Had evidence of scar-related disease or delayed healing activity within 1 year prior to study enrollment. (Note: subjects with scars were eligible for study enrollment, although scars at the intended treatment sites were not treated.)
  • Had a history of keloid formation.
  • Had a history of hypo- or hyperpigmentation of the skin.
  • Had any infection, unhealed wound, or active inflammatory process (e.g., skin eruptions such as cysts, pimples, rashes, or hives) at the injection site(s).
  • Immunocompromised/immunosuppressed (e.g., HIV-positive, transplant recipient, or presently receiving chemotherapy).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00444626
DGE00105
No
Medical Monitor, Genzyme Corporation
Genzyme, a Sanofi Company
Mentor Worldwide, LLC
Study Director: Medical Monitor Genzyme, a Sanofi Company
Genzyme, a Sanofi Company
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP